opgen
announces
award
german
government
grant
funding
subsidiary
curetis
collaborators
project
ai
based
assay
development
based
porin
loss
efflux
pump
overexpression
bacteria
project
part
research
campus
infectognostics
includes
project
partners
university
hospital
jena
institute
infectious
diseases
infection
control
gaithersburg
holzgerlingen
germany
globe
newswire
opgen
nasdaq
opgn
opgen
precision
medicine
company
harnessing
power
molecular
diagnostics
bioinformatics
help
combat
infectious
disease
announced
today
award
german
federal
government
grant
subsidiary
curetis
gmbh
collaborators
research
campus
infectognostics
project
coordinated
jena
university
hospital
designed
use
artificial
intelligence
ai
based
assay
development
based
porin
loss
efflux
pump
overexpression
bacteria
specifically
project
expected
start
september
run
august
overall
funding
thousand
euros
provided
federal
german
ministry
education
research
bundesministerium
f√ºr
bildung
und
forschung
bmbf
curetis
alone
aimed
make
novel
molecular
diagnostics
available
relevant
resistance
mechanisms
carbapenems
furthermore
project
aims
address
resistance
mechanisms
pathogens
enterobacteria
pseudomonas
acinetobacter
curetis
role
collaborative
research
project
provide
research
innovative
detection
methods
carbapenem
resistance
based
porin
loss
efflux
pump
overexpression
gerd
luedke
director
innovation
technology
ip
curetis
gmbh
commented
carbapenems
antibiotics
treatment
patients
infected
bacteria
show
resistance
cephalosporins
resistance
often
conferred
mechanisms
porin
loss
efflux
pump
overexpression
adequately
covered
current
diagnostics
therefore
excited
contribute
novel
approaches
fight
antimicrobial
resistance
hospital
oliwia
makarewicz
scientist
institute
infectious
diseases
infection
control
jena
university
hospital
leader
project
emphasizes
interdisciplinary
character
combine
molecular
genetics
bioinformatics
ai
based
methods
innovative
approach
foster
outcome
project
well
scientific
career
options
young
researchers
working
juergen
popp
speaker
infectognostics
managing
board
added
pleased
start
new
collaboration
curetis
one
leaders
rapid
multiplex
pcr
testing
project
good
example
direct
academia
clinical
medicine
industry
address
medical
needs
improved
diagnostics
regard
antimicrobial
opgen
opgen
gaithersburg
md
usa
precision
medicine
company
harnessing
power
molecular
diagnostics
bioinformatics
help
combat
infectious
disease
along
subsidiaries
curetis
gmbh
ares
genetics
gmbh
developing
commercializing
molecular
microbiology
solutions
helping
guide
clinicians
rapid
actionable
information
life
threatening
infections
improve
patient
outcomes
decrease
spread
infections
caused
microorganisms
mdros
opgen
product
portfolio
includes
unyvero
acuitas
amr
gene
panel
lighthouse
ares
technology
platform
including
aresdb
using
ngs
technology
bioinformatics
solutions
antibiotic
response
prediction
information
please
visit
statements
press
release
includes
statements
regarding
receipt
grant
german
government
curetis
gmbh
statements
statements
regarding
opgen
products
commercialization
launch
future
plans
goals
constitute
statements
within
meaning
section
securities
act
section
securities
exchange
act
intended
qualify
safe
harbor
liability
established
private
securities
litigation
reform
act
statements
subject
risks
uncertainties
often
difficult
predict
beyond
control
may
cause
results
differ
materially
expectations
factors
could
cause
results
differ
materially
described
include
limited
ability
successfully
timely
develop
seek
obtain
regulatory
clearance
commercialize
product
services
offerings
rate
adoption
products
services
hospitals
healthcare
providers
success
commercialization
efforts
impact
company
operations
financial
results
commercialization
efforts
well
capital
markets
general
economic
conditions
realization
expected
benefits
business
combination
transaction
curetis
gmbh
effect
business
existing
new
regulatory
requirements
economic
competitive
factors
discussion
significant
risks
uncertainties
associated
opgen
business
please
review
filings
securities
exchange
commission
cautioned
place
undue
reliance
statements
based
expectations
date
press
release
speak
date
press
release
undertake
obligation
publicly
update
revise
statement
whether
result
new
information
future
events
otherwise
opgen
contact
oliver
schacht
ceo
investorrelations
press
contact
matthew
bretzius
fischtank
marketing
pr
matt
investor
contact
megan
paul
edison
group
mpaul
